A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2026

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Major Depressive Disorder

Interventions

DRUG

PDC-1421 Capsule

PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Trial Locations (1)

Cedars-Sinai Health System, Los Angeles

All Listed Sponsors

collaborator

American BriVision Corporation

UNKNOWN

lead

BioLite, Inc.

INDUSTRY

NCT03833206 - A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients | Biotech Hunter | Biotech Hunter